These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 25077997)

  • 21. Predicting axillary sentinel node status in patients with primary breast cancer.
    Kolarik D; Pecha V; Skovajsova M; Zahumensky J; Trnkova M; Petruzelka L; Halaska M; Sottner O; Otcenasek M; Kolarova H
    Neoplasma; 2013; 60(3):334-42. PubMed ID: 23374005
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Variations in tumor marker levels in metastatic breast cancer patients according to tumor subtypes.
    Kos T; Aksoy S; Sendur MA; Arik Z; Civelek B; Kandemir N; Ozdemir NY; Zengin N; Altundag K
    J BUON; 2013; 18(3):608-13. PubMed ID: 24065471
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hormonal receptor, human epidermal growth factor receptor-2, and Ki67 discordance between primary breast cancer and paired metastases: clinical impact.
    Ibrahim T; Farolfi A; Scarpi E; Mercatali L; Medri L; Ricci M; Nanni O; Serra L; Amadori D
    Oncology; 2013; 84(3):150-7. PubMed ID: 23257904
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Discordant expression of hormone receptors and HER2 in breast cancer. A retrospective comparison of primary tumors with paired metachronous recurrences or metastases.
    Arapantoni-Dadioti P; Valavanis C; Gavressea T; Tzaida O; Trihia H; Lekka I
    J BUON; 2012; 17(2):277-83. PubMed ID: 22740206
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Treatment outcomes and clinicopathologic characteristics of advanced triple-negative breast cancer patients].
    Zhang P; Xu BH; Ma F; Li Q; Yuan P; Wang JY; Zhang P
    Zhonghua Zhong Liu Za Zhi; 2011 May; 33(5):381-4. PubMed ID: 21875471
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A prospective trial on initiation factor 4E (eIF4E) overexpression and cancer recurrence in node-negative breast cancer.
    Holm N; Byrnes K; Johnson L; Abreo F; Sehon K; Alley J; Meschonat C; Md QC; Li BD
    Ann Surg Oncol; 2008 Nov; 15(11):3207-15. PubMed ID: 18719964
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hormone receptors and HER2 expression in primary breast carcinoma and corresponding lymph node metastasis: do we need both?
    Raica M; Cîmpean AM; Ceausu RA; Fulga V; Nica C; Rudico L; Saptefrati L
    Anticancer Res; 2014 Mar; 34(3):1435-40. PubMed ID: 24596391
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Differences and clinical significance of receptor expression between primary and locally recurrent breast tumor tissues].
    Ma XM; Han YW; Zhang J; Cui WJ; Wang X
    Zhonghua Zhong Liu Za Zhi; 2013 May; 35(5):372-6. PubMed ID: 24054015
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Predictive factors and patterns of recurrence in patients with triple negative breast cancer.
    Steward L; Conant L; Gao F; Margenthaler JA
    Ann Surg Oncol; 2014 Jul; 21(7):2165-71. PubMed ID: 24558065
    [TBL] [Abstract][Full Text] [Related]  

  • 30. C-erbB-2 expression is a better predictor for survival than galectin-3 or p53 in early-stage breast cancer.
    Logullo AF; Lopes AB; Nonogaki S; Soares FA; Netto MM; Nishimoto IN; Brentani MM
    Oncol Rep; 2007 Jul; 18(1):121-6. PubMed ID: 17549356
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer.
    Foekens JA; Peters HA; Grebenchtchikov N; Look MP; Meijer-van Gelder ME; Geurts-Moespot A; van der Kwast TH; Sweep CG; Klijn JG
    Cancer Res; 2001 Jul; 61(14):5407-14. PubMed ID: 11454684
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A comprehensive study of oxidative stress and antioxidant status in preeclampsia and normal pregnancy.
    Llurba E; Gratacós E; Martín-Gallán P; Cabero L; Dominguez C
    Free Radic Biol Med; 2004 Aug; 37(4):557-70. PubMed ID: 15256227
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Lymph node metastasis and prognostic analysis of 354 cases of T1 breast cancer].
    Lyu Z; Wang J; Kang L; Hu C; He H; Guan M; Li J; Guan Y; Song Y
    Zhonghua Zhong Liu Za Zhi; 2014 May; 36(5):382-5. PubMed ID: 25030596
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Serum total antioxidant status and lipid peroxidation marker malondialdehyde levels in overt and subclinical hypothyroidism.
    Torun AN; Kulaksizoglu S; Kulaksizoglu M; Pamuk BO; Isbilen E; Tutuncu NB
    Clin Endocrinol (Oxf); 2009 Mar; 70(3):469-74. PubMed ID: 18727709
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Paget's disease as a local recurrence after nipple-sparing mastectomy: clinical presentation, treatment, outcome, and risk factor analysis.
    Lohsiriwat V; Martella S; Rietjens M; Botteri E; Rotmensz N; Mastropasqua MG; Garusi C; De Lorenzi F; Manconi A; Sommario M; Barbieri B; Cassilha M; Minotti I; Petit JY
    Ann Surg Oncol; 2012 Jun; 19(6):1850-5. PubMed ID: 22322949
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Analysis of margin index as a method for predicting residual disease after breast-conserving surgery in a European cancer center.
    Bolger JC; Solon JG; Power C; Hill AD
    Ann Surg Oncol; 2012 Jan; 19(1):207-11. PubMed ID: 21638098
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tumor-infiltrating lymphocytes, tumor characteristics, and recurrence in patients with early breast cancer.
    Kim ST; Jeong H; Woo OH; Seo JH; Kim A; Lee ES; Shin SW; Kim YH; Kim JS; Park KH
    Am J Clin Oncol; 2013 Jun; 36(3):224-31. PubMed ID: 22495453
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Locoregional recurrence of breast cancer: a retrospective comparison of treatment methods.
    Skowronek J; Piotrowski T
    Neoplasma; 2002; 49(6):426-31. PubMed ID: 12584593
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The prognostic significance of the percentage of positive/dissected axillary lymph nodes in breast cancer recurrence and survival in patients with one to three positive axillary lymph nodes.
    Truong PT; Berthelet E; Lee J; Kader HA; Olivotto IA
    Cancer; 2005 May; 103(10):2006-14. PubMed ID: 15812825
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Predictors of systemic recurrence and disease-specific survival after ipsilateral breast tumor recurrence.
    Shen J; Hunt KK; Mirza NQ; Buchholz TA; Babiera GV; Kuerer HM; Bedrosian I; Ross MI; Ames FC; Feig BW; Singletary SE; Cristofanilli M; Meric-Bernstam F
    Cancer; 2005 Aug; 104(3):479-90. PubMed ID: 15968686
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.